skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Rhenium-186 labeling of CC49 monoclonal antibody with N-[TRIS[2-[[N-(benzyloxy) amino] carbonyl]-ethyl]methyl] succinamic acid, trisuccin and biodistribution studies

Journal Article · · Journal of Nuclear Medicine
OSTI ID:198107
; ;  [1]
  1. Univ. of Alabama, Birmingham, AL (United States)

The use of hydroxamic acid derivatives as bifunctional chelating agents (BCAs) for radiolabeling of monoclonal antibodies, and the design and synthesis of the first member of this family, trisuccin, was recently reported. In this report, the Re-186 labeling of trisuccin-CC49 conjugate`s and their biodistribution in nude mice bearing human tumor xenografts are described. Synthesis of the BCA and conjugate preparation were as described before. Reduced (SnCl{sub 2}) Re-186 was used for labeling with 2-hydroxyisobutyric acid as the transfer ligand. The Re-186-labeled CC49 was then injected i.p. into nude mice bearing LS174T colon cancer xenografts. The injected animals were Imaged after 4 days and showed localization of the conjugate In the tumors. The biodistribution of Re-186-trisuccin-CC49 was determined at 2, 4, and 6 days after i.p. injection of 3 {mu}Ci of radioimmunoconjugate. The highest concentrations of the radioimmunoconjugate were found in tumor at all time points (6.4{plus_minus}0.9% ID/g at day 2 which decreased to 5.0{plus_minus}0.6% ID/g at 6 days after injection). The organs with the highest concentration were kidney (3.8{plus_minus}0.5% ID/g at day 2 and 1.2{plus_minus}0.1% ID/g at day 6) and liver (2.4% ID/g at day 2 and 1.3% ID/g at day 6). The tumor to normal tissue ratios for blood, kidney, and liver were 7.2, 1.7, and 2.1 at 6 days after injection, respectively. These results demonstrate that this now radioimmunoconjugate preferentially localized in the tumor.

DOE Contract Number:
FG05-93ER61654
OSTI ID:
198107
Report Number(s):
CONF-940605-; ISSN 0161-5505; CNN: Grant CA45232; TRN: 95:007029-0259
Journal Information:
Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
Country of Publication:
United States
Language:
English